行情

MDRX

MDRX

麦赛斯医药
NASDAQ

实时行情|Nasdaq Last Sale

17.89
-0.15
-0.83%
盘后: 17.89 0 0.00% 16:11 05/16 EDT
开盘
17.99
昨收
18.04
最高
18.15
最低
17.75
成交量
150.14万
成交额
0
52周最高
23.25
52周最低
13.05
市值
20.76亿
市盈率(TTM)
15.85
分时
5日
1月
3月
1年
5年
Veradigm Presentations at ISPOR 2022 Highlight Broader Access to and Integration of Real-world Data Sources
CHICAGO, May 11, 2022--Researchers from Veradigm®, a leading provider of healthcare data and technology solutions, will present health economics and outcomes research (HEOR) data on Covid-19, diabetes, NASH (Non-Alcoholic Steatohepatitis), and cardiovascul...
Business Wire · 5天前
Allscripts' (MDRX) Stock Falls 8.8% Post Q1 Earnings Miss
Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.
Zacks · 6天前
Analyst Ratings for Allscripts Healthcare
Allscripts Healthcare (NASDAQ:MDRX) has observed the following analyst ratings within the last quarter:
Benzinga · 05/06 20:32
Allscripts Healthcare Solutions falls 7% amid price target cut
Piper Sandler analyst Jeff Garro lowers price target on Allscripts Healthcare Solutions (MDRX) -7% to $19 from $22 and keeps a neutral rating after the company reported Q1 results. Analyst further states that he needs
Seekingalpha · 05/06 18:16
Research Alert: CFRA Maintains Hold On Allscripts Healthcare Solutions, Inc.
MT Newswires · 05/06 09:57
BRIEF-Allscripts Announces First Quarter Of 2022 Results
reuters.com · 05/05 22:37
AllScripts Healthcare (MDRX) Q1 Earnings and Revenues Lag Estimates
AllScripts (MDRX) delivered earnings and revenue surprises of -35% and 61.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:35
Allscripts Healthcare Solutions Non-GAAP EPS of $0.13, revenue of $142.7M; reaffirms FY22 guidance
Allscripts Healthcare Solutions press release (NASDAQ:MDRX): Q1 Non-GAAP EPS of $0.13. Revenue of $142.7M (+6.7% Y/Y). Generated $35 million of cash flow from continuing operations in the quarter. On a
Seekingalpha · 05/05 21:03
更多
暂无数据
了解MDRX最新的财务预测,通过MDRX每股收益,每股净资产,每股现金流等数据分析麦赛斯医药近期的经营情况,然后做出明智的投资选择。
分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

18.18%强力推荐
36.36%买入
36.36%中性
9.09%落后大盘
0.00%卖出
目标价格预测
分析师预测MDRX价格均价为23.44,最高价位27.00,最低价为19.00。
最高27.00
均价23.44
最低19.00
现价17.89
EPS
实际EPS
预期EPS
0.200.400.590.79
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 342
机构持股: 1.32亿
持股比例: 114.14%
总股本: 1.16亿
类型机构数股数
增持
42
680.60万
建仓
33
88.24万
减持
98
1,172.73万
平仓
33
307.26万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
先进医疗设备和技术
-0.76%
医疗设备和用品
-0.13%
高管信息
Non-Executive Chairman/Independent Director
Michael Klayko
President
Thomas Langan
Chief Executive Officer
Richard Poulton
Chief Financial Officer/Chief Accounting Officer
Leah Jones
Executive Vice President
Lisa Khorey
Senior Vice President/General Counsel
Tejal Vakharia
Director
Paul Black
Independent Director
Beth Altman
Independent Director
Mara Aspinall
Independent Director
P. Gregory Garrison
Independent Director
Jonathan Judge
Independent Director
Dave Stevens
Independent Director
David Stevens
Independent Director
Carol Zierhoffer
暂无数据
暂无数据
MDRX 简况
Allscripts Healthcare Solutions Inc是一家医疗保健信息技术解决方案和服务提供商。该公司通过两个部门运营:核心临床和财务解决方案,以及数据,分析和护理协调。核心临床和财务解决方案部门为患者参与提供软件应用程序,集成的临床和财务管理解决方案,主要包括电子健康记录相关软件,财务和实践管理软件,相关安装,支持和维护,外包,私有云托管和收入周期管理。数据,分析和护理协调部门从事实践报销,付款人和生命科学解决方案,为医生实践,付款人,生命科学公司和其他医疗保健利益相关者提供服务。

微牛提供Allscripts Healthcare Solutions Inc(NASDAQ-MDRX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MDRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MDRX股票基本功能。